Repligen (NASDAQ:RGEN) Updates FY 2025 Earnings Guidance

Repligen (NASDAQ:RGEN - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 1.670-1.760 for the period, compared to the consensus estimate of 1.710. The company issued revenue guidance of $685.0 million-$710.0 million, compared to the consensus revenue estimate of $692.8 million.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on RGEN. TD Cowen assumed coverage on Repligen in a research note on Monday, February 10th. They issued a "buy" rating and a $200.00 price objective on the stock. StockNews.com raised Repligen from a "sell" rating to a "hold" rating in a research report on Friday, January 3rd. Canaccord Genuity Group boosted their target price on Repligen from $165.00 to $170.00 and gave the company a "hold" rating in a research report on Friday. JPMorgan Chase & Co. boosted their target price on Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research report on Friday. Finally, Wolfe Research began coverage on Repligen in a research report on Thursday, November 14th. They set a "peer perform" rating on the stock. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $183.36.

Repligen Stock Down 2.3 %

Shares of RGEN stock traded down $3.68 during mid-day trading on Friday, hitting $158.99. The stock had a trading volume of 795,356 shares, compared to its average volume of 609,046. Repligen has a 12-month low of $113.50 and a 12-month high of $203.13. The firm has a market capitalization of $8.91 billion, a P/E ratio of -429.69, a price-to-earnings-growth ratio of 4.23 and a beta of 0.99. The firm's 50-day moving average is $155.22 and its two-hundred day moving average is $148.79. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. The business had revenue of $167.55 million during the quarter, compared to analysts' expectations of $167.58 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. On average, analysts predict that Repligen will post 1.54 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.